Funding for this research was provided by:
Wellcome Trust (098051)
Health Protection Agency (108077)
United Kingdom Clinical Research Collaboration (G1000803)
National Institute for Health Research (Biomedical Research Center, Cambridge)
Academy of Medical Sciences (Fellowship)
Text and Data Mining valid from 2019-09-02
Received: 4 January 2019
Accepted: 5 August 2019
First Online: 2 September 2019
Ethics approval and consent to participate
: The retrospective use of linked anonymized clinical and routine microbiology laboratory data was approved by the South Cambridgeshire Local NHS Research Ethics Committee (12/SC/0431). Research and Development (R&D) approval for whole-genome sequencing of bacteria was granted by the R&D Department at Cambridge University Hospitals NHS Foundation Trust.
: Not applicable.
: M.J.E. and N.W. perform work for Public Health Englands AMRHAI Reference Unit which has received financial support for conference attendance, lectures, research projects, or contracted evaluations from numerous sources, including Accelerate Diagnostics, Achaogen Inc., Allecra Therapeutics, Amplex, AstraZeneca UK Ltd., Basilea Pharmaceutica, Becton Dickinson Diagnostics, BioMérieux, Bio-Rad Laboratories, The BSAC, Cepheid, Check-Points B.V., Cubist Pharmaceuticals, Department of Health, Enigma Diagnostics, Food Standards Agency, GlaxoSmithKline Services Ltd., Henry Stewart Talks, IHMA Ltd., Kalidex Pharmaceuticals, Melinta Therapeutics, Merck Sharpe & Dohme Corp, Meiji Seika Pharma Co, Mobidiag, Momentum Biosciences Ltd., Nordic Pharma Ltd., Norgine Pharmaceuticals, Rempex Pharmaceuticals Ltd., Roche, Rokitan Ltd., Smith & Nephew UK Ltd., Trius Therapeutics, VenatoRx Pharmaceuticals, and Wockhardt Ltd. J.P. and S.J.P. are consultants to Next Gen Diagnostics.